Literature DB >> 16118169

Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience.

Adilson Prando1, John Kurhanewicz, Alexandre P Borges, Eduardo M Oliveira, Eduardo Figueiredo.   

Abstract

PURPOSE: To prospectively evaluate the accuracy of transrectal ultrasonography (US)-guided biopsy directed with magnetic resonance (MR) spectroscopic imaging in patients with an elevated prostate specific antigen (PSA) level and negative findings at prior biopsy by using subsequent biopsy results as the reference standard.
MATERIALS AND METHODS: The committee on human research approved this study, and written informed consent was obtained. MR imaging and MR spectroscopic imaging were performed in 42 men (age range, 45-75 years; average age, 63.3 years; median age, 65 years) with negative findings at two or more prostatic biopsies and at digital rectal examination. MR spectroscopic data were rated on a scale of 1 (benign) to 5 (malignant) on the basis of standardized metabolic criteria. Abnormal voxels were overlaid on the corresponding transverse transrectal US images and used to perform voxel-guided biopsy of the prostate. All patients subsequently received an extended-pattern biopsy scheme.
RESULTS: Thirty-one of 42 patients demonstrated metabolic abnormalities that were suspicious for cancer (voxels with scores > or = 4). Eleven patients with negative MR spectroscopic imaging results also had negative biopsy findings. Cancer was detected in 17 (55%) of 31 men with positive MR spectroscopic imaging findings (voxels with scores > or = 4) with a sensitivity of 100%, specificity of 44%, positive predictive value of 55%, negative predictive value of 100%, and accuracy of 67%. In men with at least one spectroscopic voxel with a score of 5 (12 of 17 men), the sensitivity, specificity, positive and negative predictive values, and accuracy were 71%, 84%, 75%, 81%, and 79%, respectively.
CONCLUSION: Metabolic data from MR spectroscopic imaging can be transferred to transrectal US images and used to sample regions of cancer in men with rising PSA levels and negative findings at prior biopsy with good accuracy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118169     DOI: 10.1148/radiol.2363040615

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  38 in total

1.  Magnetic resonance imaging and spectroscopy of prostate cancer.

Authors:  Peter R Carroll; Fergus V Coakley; John Kurhanewicz
Journal:  Rev Urol       Date:  2006

Review 2.  Is it time to consider a role for MRI before prostate biopsy?

Authors:  Hashim U Ahmed; Alex Kirkham; Manit Arya; Rowland Illing; Alex Freeman; Clare Allen; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

Review 3.  Proton magnetic resonance spectroscopy of the central, transition and peripheral zones of the prostate: assignments and correlation with histopathology.

Authors:  Peter Swindle; Saadallah Ramadan; Peter Stanwell; Simon McCredie; Peter Russell; Carolyn Mountford
Journal:  MAGMA       Date:  2008-09-17       Impact factor: 2.310

Review 4.  Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective.

Authors:  Ananthakrishnan Sivaraman; Kulthe Ramesh Seetharam Bhat
Journal:  Indian J Surg Oncol       Date:  2017-01-23

Review 5.  Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.

Authors:  Eva-Margarete Spur; Emily A Decelle; Leo L Cheng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-03       Impact factor: 9.236

6.  Segmented diffusion-weighted imaging of the prostate: Application to transperineal in-bore 3T MR image-guided targeted biopsy.

Authors:  Andriy Fedorov; Kemal Tuncali; Lawrence P Panych; Janice Fairhurst; Elmira Hassanzadeh; Ravi T Seethamraju; Clare M Tempany; Stephan E Maier
Journal:  Magn Reson Imaging       Date:  2016-05-27       Impact factor: 2.546

Review 7.  Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis.

Authors:  Martin Umbehr; Lucas M Bachmann; Ulrike Held; Thomas M Kessler; Tullio Sulser; Dominik Weishaupt; John Kurhanewicz; Johann Steurer
Journal:  Eur Urol       Date:  2008-10-18       Impact factor: 20.096

8.  [Prostate cancer].

Authors:  T Franiel; N Eckardt; M Waginger; M Horstmann
Journal:  Radiologe       Date:  2014-05       Impact factor: 0.635

Review 9.  Multidisciplinary functional MR imaging for prostate cancer.

Authors:  Jeong Kon Kim; Yun-Jin Jang; Gyunggoo Cho
Journal:  Korean J Radiol       Date:  2009 Nov-Dec       Impact factor: 3.500

10.  A meta-analysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool.

Authors:  Peng Wang; You-min Guo; Min Liu; Yong-qian Qiang; Xiao-juan Guo; Yi-li Zhang; Xiao-Yi Duan; Qiu-Juan Zhang; Weifeng Liang
Journal:  Korean J Radiol       Date:  2008 Sep-Oct       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.